Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

 

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cy7.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  2. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  3. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  4. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  5. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  6. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  7. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  8. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  9. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  10. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  11. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  12. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  13. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  14. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  15. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  16. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  17. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  18. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  19. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  20. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  21. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  22. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  23. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  24. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  25. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  26. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  27. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  28. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  29. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  30. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  31. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  32. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  33. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  34. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  35. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  36. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  37. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  38. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  39. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  40. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  41. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  42. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  43. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  44. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  45. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  46. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  47. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  48. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  49. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  50. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  51. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  52. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  53. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  54. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  55. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  56. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  57. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  58. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  59. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  60. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  61. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  62. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  63. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  64. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  65. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  66. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  67. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  68. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  69. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  70. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  71. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  72. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  73. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  74. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  75. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  76. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  77. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  78. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  79. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  80. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  81. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  82. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  83. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  84. Woodruff MC, et al. 2022. Nature. :. PubMed
  85. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  86. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  87. Akiyama H, et al. 2020. J Virol. . PubMed
  88. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  89. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  90. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  91. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  92. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  93. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  94. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  95. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  96. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  97. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  98. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  99. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  100. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  101. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  102. Mills C, et al. 2022. Cells. 11:. PubMed
  103. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  104. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  105. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  106. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  107. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  108. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  109. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  110. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  111. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  112. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  113. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  114. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  115. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  116. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  117. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  118. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  119. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  120. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  121. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  122. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  123. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  124. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  125. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  126. Wang Z, et al. 2021. bioRxiv. . PubMed
  127. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  128. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  129. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  130. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  131. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  132. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  133. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  134. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  135. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  136. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  137. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  138. Woodruff M, et al. 2020. medRxiv. . PubMed
  139. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  140. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  141. English KG, et al. 2022. Biomedicines. 10:. PubMed
  142. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  143. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  144. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  145. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  146. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  147. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  148. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  149. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  150. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  151. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  152. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  153. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  154. Popay TM, et al. 2021. Elife. 10: . PubMed
  155. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  156. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  157. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  158. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  159. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  160. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  161. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  162. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  163. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  164. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  165. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  166. Ito Y, et al. 2018. Cell. 174:636. PubMed
  167. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  168. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  169. Elias G, et al. 2022. Elife. 11:. PubMed
  170. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  171. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  172. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  173. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  174. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  175. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  176. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  177. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  178. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  179. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  180. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  181. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  182. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  183. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  184. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  185. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  186. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  187. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  188. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  189. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  190. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  191. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  192. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  193. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  194. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  195. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  196. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  197. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  198. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  199. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  200. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  201. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  202. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  203. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  204. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  205. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  206. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  207. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  208. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  209. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  210. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  211. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  212. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  213. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  214. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  215. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  216. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  217. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  218. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  219. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  220. Wang Z, et al. 2021. Nature. 592:616. PubMed
  221. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  222. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  223. Dudek M, et al. 2021. Nature. 592:444. PubMed
  224. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  225. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  226. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  227. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  228. He Y, et al. 2022. Cells. 11:. PubMed
  229. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  230. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  231. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  232. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  233. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  234. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  235. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  236. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  237. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  238. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  239. Wang Z, et al. 2021. Nature. 595:426. PubMed
  240. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  241. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  242. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  243. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  244. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  245. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  246. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  247. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  248. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  249. Korin B, et al. 2020. Sleep. :43. PubMed
  250. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  251. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  252. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  253. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  254. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  255. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  256. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  257. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  258. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  259. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  260. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  261. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  262. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  263. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  264. Gaebler C, et al. 2020. bioRxiv. . PubMed
  265. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  266. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  267. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  268. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  269. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  270. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  271. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  272. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  273. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  274. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  275. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  276. Viant C, et al. 2020. Cell. 183:1298. PubMed
  277. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  278. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  279. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  280. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  281. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  282. Sibler E, et al. 2021. Cells. 10:. PubMed
  283. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  284. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  285. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  286. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  287. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  288. Spath S, et al. 2022. iScience. 25:104998. PubMed
  289. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  290. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  291. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  292. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  293. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  294. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  295. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  296. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  297. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  298. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  299. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  300. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  301. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  302. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  303. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  304. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  305. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  306. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  307. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 5    Revision Date: 05.20.2020

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account